Page last updated: 2024-12-11
azd9272
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
AZD9272: an mGluR5 antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9838729 |
CHEMBL ID | 2164550 |
CHEMBL ID | 2164551 |
SCHEMBL ID | 2027395 |
MeSH ID | M0578549 |
Synonyms (26)
Synonym |
---|
3-fluoro-5-[3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]benzonitrile |
CHEMBL2164550 , |
bdbm50395923 |
azd-9272 |
CHEMBL2164551 |
azd9272 |
gtpl6439 |
azd 9272 |
RBSPCALDSNXWEP-UHFFFAOYSA-N , |
5-(3-cyano-5-fluorophenyl)-3-(5-fluoro-pyrid-2-yl)-1,2,4-oxadiazole |
SCHEMBL2027395 |
unii-54sq9b412i |
azd 9272 [who-dd] |
54SQ9B412I , |
3-fluoro-5-(3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl)benzonitrile |
3-(5-fluoropyridyl-2-yl)-5-(3-cyano-5-fluorophenyl)-1,2,4-oxadiazole |
benzonitrile, 3-fluoro-5-(3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl)- |
327056-26-8 |
3-fluoro-5-[3-(5-fluoro-2-pyridinyl)-1,2,4-oxadiazol-5-yl]benzonitrile |
azd9272, >=98% (hplc) |
AKOS027470228 |
Q27074816 |
CS-0033119 |
HY-110254 |
CNA05626 |
EX-A7965 |
Research Excerpts
Overview
AZD9272 is a new chemical entity pharmacologically characterised as a noncompetitive antagonist at the metabotropic glutamate receptor subtype 5 (mGluR5)
Excerpt | Reference | Relevance |
---|---|---|
"AZD9272 is a new chemical entity pharmacologically characterised as a noncompetitive antagonist at the metabotropic glutamate receptor subtype 5 (mGluR5)." | ( Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers. Cselényi, Z; Hooker, AC; Jönsson, S; Kågedal, M; Karlsson, MO; Nyberg, S; Raboisson, P; Stenkrona, P, 2012) | 1.1 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (3)
Inhibition Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Metabotropic glutamate receptor 5 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0026 | 0.0000 | 0.5262 | 7.9700 | AID697344 |
Metabotropic glutamate receptor 5 | Homo sapiens (human) | IC50 (µMol) | 0.0168 | 0.0005 | 0.4394 | 10.0000 | AID697343; AID697601 |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 (µMol) | 33.0000 | 0.0009 | 1.9014 | 10.0000 | AID697602 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (42)
Molecular Functions (20)
Ceullar Components (13)
Bioassays (43)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID697581 | Antagonist activity at mGluR7 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697604 | Negative allosteric modulation of human recombinant mGluR5 expressed in HEK293 cells expressing GLAST assessed as inhibition of ATP-induced intracellular Ca2+ level at 10 uM after 30 mins by FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697598 | Equilibrium solubility of the compound in DMSO | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697343 | Negative allosteric modulation of human recombinant mGluR5 expressed in HEK293 cells expressing GLAST assessed as inhibition of DHPG-induced intracellular Ca2+ level after 30 mins by FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697585 | Antagonist activity at mGluR2 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697597 | Cmax in Sprague-Dawley rat at 3 umol/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697577 | Positive allosteric modulation of mGluR3 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697573 | Positive allosteric modulation of mGluR8 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697563 | Tmax in Sprague-Dawley rat at 3 umol/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697567 | Plasma protein binding in Sprague-Dawley rat after 6 hrs by equilibrium dialysis method | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697602 | Inhibition of human ERG by IonWorks assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697589 | Agonist activity at mGluR6 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697582 | Antagonist activity at mGluR6 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697586 | Antagonist activity at mGluR1 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697584 | Antagonist activity at mGluR3 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697579 | Positive allosteric modulation of mGluR1 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697568 | Ratio of drug level in brain to plasma of Sprague-Dawley rat at 3 umol/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697601 | Negative allosteric modulation of human recombinant mGluR5 expressed in HEK293 cells expressing GLAST assessed as inhibition of glutamate-stimulated IP accumulation incubated for 10 mins prior to glutamate challenge measured 30 mins post glutamate challen | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697600 | Intrinsic clearance in human liver microsomes | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697587 | Agonist activity at mGluR8 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697590 | Agonist activity at mGluR4 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697606 | Negative allosteric modulation of human recombinant mGluR5 expressed in HEK293 cells expressing GLAST assessed as inhibition of DHPG-induced intracellular Ca2+ level at 0.001 to 3 uM after 30 mins by FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697588 | Agonist activity at mGluR7 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697583 | Antagonist activity at mGluR4 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697566 | Oral bioavailability in Sprague-Dawley rat at 3 umol/kg | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697562 | Clearance in Sprague-Dawley rat at 3 umol/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697599 | Intrinsic clearance in rat liver microsomes | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697564 | AUC in Sprague-Dawley rat at 3 umol/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697575 | Positive allosteric modulation of mGluR6 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697592 | Agonist activity at mGluR2 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697578 | Positive allosteric modulation of mGluR2 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697344 | Negative allosteric modulation of rat recombinant mGluR5 expressed in HEK293 cells expressing GLAST assessed as inhibition of DHPG-induced intracellular Ca2+ level after 30 mins by FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697605 | Negative allosteric modulation of rat recombinant mGluR5 expressed in HEK293 cells expressing GLAST assessed as inhibition of DHPG-induced intracellular Ca2+ level at 0.001 to 3 uM after 30 mins by FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697594 | Volume of distribution at steady state in Sprague-Dawley rat at 3 umol/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697593 | Agonist activity at mGluR1 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697574 | Positive allosteric modulation of mGluR7 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697560 | Terminal half life in Sprague-Dawley rat at 3 umol/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697580 | Antagonist activity at mGluR8 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697576 | Positive allosteric modulation of mGluR4 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697603 | Negative allosteric modulation of rat recombinant mGluR5 expressed in HEK293 cells expressing GLAST assessed as inhibition of ATP-induced intracellular Ca2+ level at 10 uM after 30 mins by FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697607 | Noncompetitive inhibition of human mGluR5 expressed in HEK cells assessed as inhibition of DHPG-induced intracellular Ca2+ level at 10 to 300 nM after 30 mins by FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID697591 | Agonist activity at mGluR3 assessed as effect on intracellular Ca2+ level up to 30 uM by cell based FLIPR assay | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
AID1346269 | Human mGlu5 receptor (Metabotropic glutamate receptors) | 2012 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22 | Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (83.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.43
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.43) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (16.67%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (83.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |